Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023
- Larger order for 2023 follows initial order for supply in 2022
COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered a new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS® smallpox/monkeypox vaccine. Deliveries and all revenues under this contract will occur in 2023 and thus the order has no impact on the financial guidance for this year.
Bavarian Nordic signed its first supply contract with this country earlier this summer to ensure deliveries in 2022, which have recently started.
Paul Chaplin, President and CEO of Bavarian Nordic said: “While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts.”
With this order, together with previously announced orders from the US, Canada and other countries, Bavarian Nordic now has significant orders of smallpox/monkeypox vaccines, providing a robust basis for 2023.
About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. In addition to smallpox, the U.S. Food and Drug Administration, Health Canada and the European Commission have also approved the vaccine for use against monkeypox as the only vaccine having obtained this to-date.
Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, smaller quantities of the vaccine have been supplied in response to sporadic cases of monkeypox. During the ongoing 2022 outbreak of monkeypox, Bavarian Nordic has worked with several governments to fulfil the immediate demand for the vaccine through a number of supply agreements and is working to secure manufacturing of vaccines to fulfil the demand in the medium- to long term.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, email@example.com, Tel: +1 781 686 9600
Company Announcement no. 30 / 2022
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Valberedning inför Industrivärdens årsstämma 20233.10.2022 10:00:00 CEST | Pressemelding
Enligt det beslut om valberedningen som fattades vid årsstämman 2011, och som gäller tillsvidare, uppdras åt styrelsens ordförande att ta kontakt med fyra bland de röstmässigt största ägarregistrerade aktieägarna i Euroclear Sweden AB:s utskrift av aktieboken per sista bankdagen i augusti, som vardera utser en representant som inte är ledamot i bolagets styrelse att jämte ordföranden utgöra valberedning för tiden intill dess att ny valberedning utsetts. Valberedningen utser ordföranden inom gruppen. Sammansättningen av valberedningen ska tillkännages senast sex månader före nästa årsstämma. Inget arvode ska utgå. I enlighet härmed har valberedningen följande sammansättning: Mats Guldbrand, L E Lundbergföretagen, Bo Damberg, Jan Wallanders och Tom Hedelius stiftelse m fl, Jan Svedjebrant, SCA Pensionsstiftelser m fl, Mikael Schmidt, Essity Pensionsstiftelser m fl, samt Fredrik Lundberg, styrelseordförande i Industrivärden. Om ledamot lämnar valberedningen innan dess arbete är slutfört,
Nominating committee ahead of Industrivärden’s 2023 AGM3.10.2022 10:00:00 CEST | Press release
In accordance with a resolution for the Nominating Committee made by the 2011 Annual General Meeting, and which applies until further notice, the Chairman of the Board is assigned the task of contacting four shareholders from among the largest registered shareholders in terms of votes in Euroclear Sweden AB's printout of the shareholder register as per the last business day in August, who each appoints one representative who is not a director on the Company's board, to form together with the Chairman of the Board a Nominating Committee for the time until a new Nominating Committee has been appointed. The Nominating Committee appoints a committee chair from among its members. The composition of the Nominating Committee shall be made public not later than six months before the next Annual General Meeting. No fee is payable for work on the Nominating Committee. Accordingly, the Nominating Committee has the following composition: Mats Guldbrand, L E Lundbergföretagen, Bo Damberg, Jan Walla
Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS)3.10.2022 08:55:00 CEST | Press release
SAMPO PLC MANAGERS’ TRANSACTIONS 3 October 2022 at 9:55 am Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. The transaction concerns the change of ownership in Alectoris AS. After the transaction, Wahlroos doesn’t have controlling interest in Alectoris AS. ____________________________________________ Person subject to the notification requirement Name: Björn Wahlroos Position: Member of the Board/Deputy member Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 20225/5/4 ____________________________________________ Transaction date: 2022-09-27 Venue not applicable Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: GIFT, DONATION OR INHERITANCE (MADE) Transaction details (1): Volume: 570,000 Unit price: 0 N/A Aggregated transactions (1): Volume: 570,000 Volume weighted average price: 0 N/
Norsk Hydro: Status share buyback program3.10.2022 08:10:00 CEST | Press release
Please see below information about transactions made under the share buy-back program for Norsk Hydro ASA. Announcement date of the share buyback program: September 23, 2022 End date of the share buyback program: March 29, 2023 Overview of transactions: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055.919 895 23827.09.2022170 00057.779 820 30528.09.2022178 00055.879 945 44729.09.2022170 00057.679 803 52630.09.2022170 00058.539 950 746Total transactions under the program:865 00057.1349 415 263 Following the above listed transactions, Norsk Hydro ASA owns a total of 17 317 403 shares, corresponding to 0.84% of Norsk Hydro ASA's share capital. Attachment: An overview of all the completed transactions under the program for the dates specified above is attached to this notification and available on www.newsweb.no. This is information that Norsk Hydro ASA is obliged to make public pursuant to the EU Market Abuse
Norsk Hydro: Status tilbakekjøp av egne aksjer3.10.2022 08:10:00 CEST | Pressemelding
Nedenfor er informasjon om transaksjoner foretatt under tilbakekjøpsprogrammet for Norsk Hydro ASA. Dato for når tilbakekjøpsprogrammet ble annonsert: 23. september 2022 Tilbakekjøpsprogrammets varighet: 29. mars 2023 Oversikt over transaksjoner: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055,919 895 23827.09.2022170 00057,779 820 30528.09.2022178 00055,879 945 44729.09.2022170 00057,679 803 52630.09.2022170 00058,539 950 746Total transactions under the program:865 00057,1349 415 263 Etter gjennomføringen av overnevnte transaksjoner, eier Norsk Hydro ASA totalt 17 317 403 egne aksjer, tilsvarende 0,84% av Norsk Hydro ASAs aksjekapital. Vedlegg: En oversikt over alle gjennomførte handler under tilbakekjøpsprogrammet som er uført i overnevnte tidsperiode er vedlagt denne meldingen og tilgjengelig på www.newsweb.no. Denne opplysningen er informasjonspliktig i henhold til EUs Market Abuse Regulation og krav